M Weisser1, C Theilacker2, S Tschudin Sutter1, R Babikir3, H Bertz4, T Götting3, M Dettenkofer3, W V Kern5, A F Widmer6. 1. Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. 2. Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany. 3. Department of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany. 4. Division of Haematology, Oncology and Stem Cell Transplantation, University Hospital and Medical Centre, Germany. 5. Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, and Faculty of Medicine, Albert-Ludwigs-University, Freiburg, Germany. 6. Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. Electronic address: andreas.widmer@usb.ch.
Abstract
OBJECTIVES: Antibacterial resistance is emerging in patients undergoing haematopoietic stem cell transplantation (HSCT), and most data on the epidemiology of bloodstream infections (BSI)-causing pathogens come from retrospective single-centre studies. This study sought to investigate trends in the epidemiology of BSI in HSCT patients from a prospective multicentre cohort. METHODS: We investigated changes in the incidence of causative organisms of BSI during neutropenia among adult HSCT patients for 2002-2014. The data were collected from a prospective cohort for infection surveillance in 20 haematologic cancer centres in Germany, Austria and Switzerland (ONKO-KISS). RESULTS: A total of 2388 of 15 181 HSCT patients with neutropenia (1471 allogeneic (61.6%) and 917 autologous (38.4%) HSCT) developed BSI (incidence 15.8% per year). The incidence of Gram-negative BSI increased over time both in patients after allogeneic HSCT (allo-HSCT) and autologous HSCT (auto-HSCT). BSI caused by Escherichia coli in allo-HSCT patients increased from 1.1% in 2002 to 3.8% in 2014 (3/279 vs. 31/810 patients, p <0.001), and the incidence of BSI caused by enterococci increased from 1.8% to 3.3% (5 vs. 27 patients, p <0.001). In contrast, the incidence of BSI due to coagulase-negative staphylococci decreased in allo-HSCT patients from 8.2% to 5.1%, (23 vs. 40 patients, p <0.001) and in auto-HSCT patients from 7.7% to 2.0% (13/167 vs. 30/540 patients; p = 0.028 for period 2002-2011). No significant trends were observed for the incidence of BSI due to methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci or extended-spectrum β-lactamase-producing Enterobacteriaceae. The BSI case fatality remained unchanged over the study period (total of 477 fatalities, 3.1%). CONCLUSIONS: The incidence of Gram-negative BSI significantly increased over time in this vulnerable patient population, providing evidence for reevaluating empiric therapy for neutropenic fever in HSCT patients.
OBJECTIVES: Antibacterial resistance is emerging in patients undergoing haematopoietic stem cell transplantation (HSCT), and most data on the epidemiology of bloodstream infections (BSI)-causing pathogens come from retrospective single-centre studies. This study sought to investigate trends in the epidemiology of BSI in HSCT patients from a prospective multicentre cohort. METHODS: We investigated changes in the incidence of causative organisms of BSI during neutropenia among adult HSCT patients for 2002-2014. The data were collected from a prospective cohort for infection surveillance in 20 haematologic cancer centres in Germany, Austria and Switzerland (ONKO-KISS). RESULTS: A total of 2388 of 15 181 HSCT patients with neutropenia (1471 allogeneic (61.6%) and 917 autologous (38.4%) HSCT) developed BSI (incidence 15.8% per year). The incidence of Gram-negative BSI increased over time both in patients after allogeneic HSCT (allo-HSCT) and autologous HSCT (auto-HSCT). BSI caused by Escherichia coli in allo-HSCT patients increased from 1.1% in 2002 to 3.8% in 2014 (3/279 vs. 31/810 patients, p <0.001), and the incidence of BSI caused by enterococci increased from 1.8% to 3.3% (5 vs. 27 patients, p <0.001). In contrast, the incidence of BSI due to coagulase-negative staphylococci decreased in allo-HSCT patients from 8.2% to 5.1%, (23 vs. 40 patients, p <0.001) and in auto-HSCT patients from 7.7% to 2.0% (13/167 vs. 30/540 patients; p = 0.028 for period 2002-2011). No significant trends were observed for the incidence of BSI due to methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci or extended-spectrum β-lactamase-producing Enterobacteriaceae. The BSI case fatality remained unchanged over the study period (total of 477 fatalities, 3.1%). CONCLUSIONS: The incidence of Gram-negative BSI significantly increased over time in this vulnerable patient population, providing evidence for reevaluating empiric therapy for neutropenic fever in HSCT patients.
Authors: Andreas F Widmer; Winfried V Kern; Jan A Roth; Markus Dettenkofer; Tim Goetting; Hartmut Bertz; Christian Theilacker Journal: Infection Date: 2019-06-11 Impact factor: 3.553
Authors: Sarah M Heston; Rebecca R Young; Hwanhee Hong; Ibukunoluwa C Akinboyo; John S Tanaka; Paul L Martin; Richard Vinesett; Kirsten Jenkins; Lauren E McGill; Kevin C Hazen; Patrick C Seed; Matthew S Kelly Journal: Open Forum Infect Dis Date: 2020-09-30 Impact factor: 3.835